Nagai T
First Department of Internal Medicine, Gunma University School of Medicine, Japan.
J Atheroscler Thromb. 1994;1(1):37-40. doi: 10.5551/jat1994.1.37.
Lipoprotein (a) (Lp(a)) is a plasma lipoprotein of high atherogenicity and competes with plasminogen at the site of plasminogen receptors. It is known that diabetic patients show a hypercoagulable state which might contribute to diabetic vascular complications. In the present study, mean levels of plasma Lp(a) and parameters of coagulation and fibrinolysis such as thrombin-antithrombin III complex (TAT) and alpha 2 plasmin inhibitor-plasmin complex (alpha 2PIC) were elevated in diabetic patients with nephropathy compared to healthy controls. A significant positive correlation was observed between the plasma levels of Lp(a) and alpha 2PIC (p < 0.05). Plasma levels of alpha 2PIC showed a significant positive correlation with those of TAT in the diabetic group, while there was no significant correlation observed in the non-diabetic group. The present results suggest that factors of Lp(a) and coagulation-fibrinolytic systems interacted, contributing to vascular complications in diabetic patients with nephropathy.
脂蛋白(a) [Lp(a)]是一种具有高度致动脉粥样硬化性的血浆脂蛋白，它在纤溶酶原受体部位与纤溶酶原竞争。已知糖尿病患者呈现高凝状态，这可能导致糖尿病血管并发症。在本研究中，与健康对照相比，糖尿病肾病患者的血浆Lp(a)平均水平以及凝血和纤溶参数，如凝血酶-抗凝血酶III复合物(TAT)和α2纤溶酶抑制物-纤溶酶复合物(α2PIC)均升高。观察到Lp(a)的血浆水平与α2PIC之间存在显著正相关(p < 0.05)。在糖尿病组中，α2PIC的血浆水平与TAT的血浆水平呈显著正相关，而在非糖尿病组中未观察到显著相关性。目前的结果表明，Lp(a)和凝血-纤溶系统的因素相互作用，导致糖尿病肾病患者出现血管并发症。
